Drug Patents owned by Novo Nordisk Inc

1. List of Vagifem drug patents

VAGIFEM's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7018992 NOVO NORDISK INC Hormone composition
Sep, 2022

(8 months ago)

Do you want to check out VAGIFEM patents from before 2022?

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 26 March, 1999

Treatment: Treatment of atrophic vaginitis due to menopause

Dosage: TABLET;VAGINAL

How can I launch a generic of VAGIFEM before it's patent expiration?
More Information on Dosage

VAGIFEM family patents

6

Denmark

5

United States

3

European Union

2

Germany

2

Spain

2

Japan

1

Cyprus

1

Australia

1

Portugal

1

Austria

2. List of Victoza drug patents

VICTOZA's oppositions filed in EPO
VICTOZA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(9 months ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618 NOVO NORDISK INC Stable formulation of modified GLP-1
Jun, 2022

(11 months ago)

US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1
Dec, 2022

(5 months ago)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs
Feb, 2023

(3 months ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(26 days from now)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(6 months from now)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(11 months from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(1 year, 5 months from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(2 years from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(9 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button
Mar, 2033

(9 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(13 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(14 years from now)

Do you want to check out VICTOZA patents from before 2022?
Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jun 17, 2022
Pediatric Exclusivity (PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's patent expiration?
More Information on Dosage

VICTOZA family patents

22

United States

18

Denmark

14

European Union

7

Spain

7

Japan

7

China

5

Australia

5

Portugal

5

Poland

4

Canada

4

Austria

4

Russia

4

Germany

3

Slovenia

3

Brazil

3

Hungary

2

Korea, Republic of

2

Mexico

1

Israel

1

Croatia

1

Chile

1

Cyprus

1

Philippines

1

Morocco

1

Hong Kong

1

South Africa

1

RS

1

Turkey

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic